KR930702019A - 피부.각막 질환 치료제 - Google Patents

피부.각막 질환 치료제

Info

Publication number
KR930702019A
KR930702019A KR1019930701416A KR930701416A KR930702019A KR 930702019 A KR930702019 A KR 930702019A KR 1019930701416 A KR1019930701416 A KR 1019930701416A KR 930701416 A KR930701416 A KR 930701416A KR 930702019 A KR930702019 A KR 930702019A
Authority
KR
South Korea
Prior art keywords
skin
agent
disease treatment
cpb
corneal disease
Prior art date
Application number
KR1019930701416A
Other languages
English (en)
Other versions
KR100191192B1 (ko
Inventor
히로시 나카오
타카오 나고야
요시 사이노
Original Assignee
미와 타카야수
코와 가부시키카이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of KR930702019A publication Critical patent/KR930702019A/ko
Application filed by 미와 타카야수, 코와 가부시키카이샤 filed Critical 미와 타카야수
Application granted granted Critical
Publication of KR100191192B1 publication Critical patent/KR100191192B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

CPB-I 또는 리콤비난트 CPB-I를 유효성분으로 하는 피부 각막질환치료제, 이 CPB-I 및 리콤비난트 CPB-I은 우수한 선유아세포의 육아의 신생촉진작용 및 각막내피세포, 표피세포 등의 늘림 작용을 가지며 활성을 저하시키는 작용을 갖고 있기 때문에 병용이 가능하며, 치유효과의 향상이 기대된다.
따라서 본 발명 약제는 모든 피부나 각막의 질환, 특히 창상 및 건선의 치료에 대하여 극히 유용한 것이다.

Description

피부.각막 질환 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 (1)~(3)은 각가 시험예 1에서 HNEK, HUVEC 및 Flow 2000의 늘림에 대한 작용에 대해서의 시험결과를 나타낸 도면이다, 제2도 (1)~(3)은 각각 시험예 2에서 Flow 2000, HUVEC 및 HNEK의 접착에 대한 작용에 대해서의 시험결과를 나타낸 도면이다, 제3도 시험예 4에서 PKC 활성에 대한 작용에 대해서의 시험결과를 나타낸 도면이다, 제4도 시험예 5에서 PKC 활성에 대한 작용에 대해서의 시험결과를 나타낸 도면이다.

Claims (3)

  1. CPB-I 또는 리콤비난트 CPB-I를 유효성분으로 하는 피부.각막질환 치료제.
  2. 창상 또는 건선치료에 사용하는 것인 청구항 1항 기재의 피부.각막질환 치료제.
  3. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930701416A 1990-11-20 1997-11-19 피부.각막 질환 치료제 KR100191192B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP31464890 1990-11-20
JP314648/1990 1990-11-20
JP90-314648 1990-11-20
PCT/JP1991/001587 WO1992008475A1 (fr) 1990-11-20 1991-11-19 Agent therapeutique pour la peau ou contre les maladies corneennes

Publications (2)

Publication Number Publication Date
KR930702019A true KR930702019A (ko) 1993-09-08
KR100191192B1 KR100191192B1 (ko) 1999-06-15

Family

ID=18055860

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930701416A KR100191192B1 (ko) 1990-11-20 1997-11-19 피부.각막 질환 치료제

Country Status (11)

Country Link
US (1) US5360789A (ko)
EP (1) EP0558751B1 (ko)
JP (1) JP3126733B2 (ko)
KR (1) KR100191192B1 (ko)
AT (1) ATE189393T1 (ko)
CA (1) CA2096520C (ko)
DE (1) DE69131964T2 (ko)
DK (1) DK0558751T3 (ko)
ES (1) ES2143467T3 (ko)
GR (1) GR3033157T3 (ko)
WO (1) WO1992008475A1 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511762A (en) 1993-07-19 2003-09-26 Univ British Columbia Anti-angiogenic compositions and methods of use
US20030203976A1 (en) * 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US5698533A (en) * 1994-07-26 1997-12-16 Kang; Meng-Che Ophthalmic pharmaceutical composition
JPH0848634A (ja) * 1994-08-05 1996-02-20 Akio Okamoto 角膜治療剤
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
ATE470449T1 (de) * 2000-08-10 2010-06-15 Santen Pharmaceutical Co Ltd Förderer der hautwundheilung
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
EP1839670A3 (en) * 2001-02-21 2009-11-11 Alavita Pharmaceuticals, Inc. Modified Annexin Proteins and their use against thrombosis
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US20050222030A1 (en) * 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
CN1267150C (zh) * 2001-02-26 2006-08-02 兴和株式会社 滴眼剂
AU2003903896A0 (en) * 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
CA2720280C (en) 2008-04-01 2018-02-20 Mosamedix B.V. Annexin a5 for reducing scar formation in wound healing

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1265446A (en) * 1985-09-30 1990-02-06 Masahiro Maki Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component
JPH0764878B2 (ja) * 1986-10-14 1995-07-12 興和株式会社 抗血液凝固物質及びその製法
US4937324A (en) * 1987-02-06 1990-06-26 Zymogenetics, Inc. Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity
JP2660514B2 (ja) * 1987-02-20 1997-10-08 興和株式会社 抗血液凝固作用を有するポリペプチド
JPH06799B2 (ja) * 1987-04-02 1994-01-05 帝人株式会社 起炎性フオスフオリパ−ゼａ▲下２▼阻害活性を有する蛋白
ES2096556T3 (es) * 1988-02-26 1997-03-16 Biogen Inc Secuencias de adn, moleculas de adn recombinante y procedimientos para producir lipocortinas iii, iv, v y vi.
US5179081A (en) * 1988-07-21 1993-01-12 Kowa Co., Ltd. Method of treatment using an anticoagulant polypeptide

Also Published As

Publication number Publication date
DK0558751T3 (da) 2000-05-08
KR100191192B1 (ko) 1999-06-15
DE69131964T2 (de) 2000-05-18
CA2096520A1 (en) 1992-05-21
ES2143467T3 (es) 2000-05-16
WO1992008475A1 (fr) 1992-05-29
DE69131964D1 (de) 2000-03-09
JP3126733B2 (ja) 2001-01-22
ATE189393T1 (de) 2000-02-15
CA2096520C (en) 2000-12-19
EP0558751B1 (en) 2000-02-02
GR3033157T3 (en) 2000-08-31
US5360789A (en) 1994-11-01
EP0558751A1 (en) 1993-09-08
EP0558751A4 (en) 1994-07-13

Similar Documents

Publication Publication Date Title
KR930702019A (ko) 피부.각막 질환 치료제
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
ATE32730T1 (de) Indikatormarkierte konjugate von metallothionein und zielsuchenden, biologisch aktiven molekuelen.
KR890011606A (ko) 항응고제
DE69421778D1 (de) Verwendung von wirksamen Mengen von aktiven Stoffen zur Behandlung von Mischhaut
IT1229195B (it) Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
ATE79761T1 (de) Behandlung einer krankheit vom aids-typ.
ES2063060T3 (es) Benzamida contra enfermedades cognoscitivas.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
KR920016088A (ko) 하부 요로 질환의 치료
KR950701820A (ko) 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
ATE68182T1 (de) Thiophensulfonamide zur behandlung von glaukom.
ES2196027T3 (es) Tratamiento de enfermedades vasculares degenerativas mediante modulacion de la produccion o actividad del oxido nitrico exogeno.
DE68912020D1 (de) N-2,3-Butadienyl-tri-aminoalkanderivate.
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
AR246077A1 (es) Benzoil-ureas que tienen actividad insecticida.
DE68919009T2 (de) Verwendung von 5-Amino-salicylsäure für die Behandlung von Hautkrankheiten.
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
DE3587160T2 (de) Anwendung von Sterolinen und Spiroketalinen zur Herstellung von Medikamenten zur Behandlung von Psoriasis.
ATE117549T1 (de) Lysyl-oxidase-inhibitoren.
DE69943240D1 (de) Verwendung von HGF für die Behandlung von ischämischen Erkrankungen der Extremitäten
ATE120799T1 (de) Mutein von hst-1 und seine herstellung.
DE59504374D1 (de) Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
KR900012622A (ko) 피부질환치료 조성물

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090112

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee